Who is this relevant for?
- Manufacturers evaluating market entry for non-hormonal therapies targeting ADT side effects
Androgen deprivation therapy (ADT) for prostate cancer triggers hot flushes in a majority of patients. These episodes are persistent, often severe, and remain underdiagnosed. Current options like SSRIs or anticholinergics offer limited efficacy and side effects of their own.
Recent insights into KNDy neuron dysfunction provide a new target. These neurons regulate thermoregulation via neurokinin B signaling. Blocking the neurokinin 3 receptor (NK3R) with antagonists like fezolinetant or elinzanetant has shown efficacy in menopausal hot flushes. The same mechanism applies to ADT-induced cases, as demonstrated in preclinical and clinical studies.
The clinical rationale is robust: non-hormonal, mechanism-driven intervention. No estrogenic effects, no hormonal disruption. For manufacturers, this opens a clear pathway to repurpose or develop NK3R antagonists for the prostate cancer population.
Market potential is significant. ADT is used in both localized and advanced prostate cancer, often for years. A targeted, well-tolerated treatment for hot flushes would address an unmet need and improve quality of life. Regulatory precedent from menopause indications (e.g., fezolinetant approved in some regions) may accelerate development.
Operationally, manufacturers should note the need for prostate-cancer-specific trials. The mechanism is shared, but dosing, safety, and drug interactions must be verified in ADT patients. Early movers could capture a niche with high patient demand and limited competition.